The benefits of a one-time gene therapy were sustained for up to 13 years among men with severe hemophilia B with no new safety concerns emerging, according to newly published results from a clinical trial. The findings, which encompass the longest ever follow-up for a gene therapy study in…

A small survey study in Germany found that many people with severe hemophilia are not interested in receiving gene therapy, despite having “only general knowledge” of the treatment option — which, the researchers noted, could be “a potential cure with a single infusion.” According to the scientists, these…

Combining the bypassing agents Novoseven and Feiba, with extended time between doses, could be a successful and cost-effective protocol to manage bleeding episodes in hemophilia A patients with inhibitors, according to a retrospective study. The study, “Combination of Novoseven and Feiba in hemophiliac patients with inhibitors,” was published in…

When used long term, Novoeight (turoctocog alfa) safely and effectively prevented and treated bleeding episodes in people with hemophilia A in Japan, according to a real-world study. In fact, Novoeight successfully treated 91.4% of the reported bleeds, and kept bleeding under control in 85.7% of surgical procedures. Moreover,…

When my oldest son was 2 years old, he came up to me with a serious expression and said, “Dad, this monster slapped me right in the face.” I told him I had some monster spray in my room and would ensure that his room no longer contained any strange-looking…

In January 2017, I lost my mother, who had fought cancer for several years. I fell into a deep depression, and then suddenly found out I was pregnant. The new life inside of me helped me slightly overcome the depression. I started taking better care of myself and researching…

Dear Chronically Ill Partner, I know life isn’t always easy for you. You have grown up believing life dealt you a terrible deck of cards. You’re no stranger to the feeling of suffering. At one point or another, you’ve even questioned the motives of the universe in…

Pregnant women who are hemophilia B carriers have more than three times the risk of bleeding following childbirth than non-carriers, a register-based study done in Sweden has found. In contrast, researchers found no differences in the risk of postpartum bleeding between hemophilia A carriers and non-carriers, or in the…

Nuwiq (simoctocog alfa) effectively prevented and controlled bleeds in previously untreated people with severe hemophilia A, according to data from a Phase 3 clinical trial. Full trial results were reported in the study, “Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A — Final efficacy…

After five years of follow-up, Hemgenix (etranacogene dezaparvovec-drlb) was associated with durable factor IX (FIX) levels, lower bleeding rates, and a substantial reduction in the need for regular FIX infusions, with a generally favorable long-term safety profile in men with severe or moderately severe hemophilia B. These data…